Search This Blog

Tuesday, August 27, 2019

AMAG Pharma launches Vyleesi in U.S.

AMAG Pharmaceuticals (NASDAQ:AMAG) announces the commercial availability of female hypoactive sexual desire disorder med Vyleesi (bremelanotide injection) through specialty pharmacies Avella and BioPlus.
The FDA approved it two months ago.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)